Scope and commitment
Weave Bio is a platform play — you buy an AI-native submissions workspace and commit to an implementation, with the company building toward full lifecycle coverage over time. Regfo is a point solution: a team can start with a study report in the morning and be reviewing the first compliance dashboard the same afternoon. If you are about to file an IND, the point solution gets you there first. If you are centralising regulatory across a growing portfolio, the platform story is stronger.
Regfo
Narrow and sharp — the job is the IND window, nothing else fighting for attention.
Weave Bio
Wide and integrated — worth it when the whole lifecycle is in scope.
Analytical depth on preclinical gaps
The specific thing a regulatory lead cares about two weeks before filing is: "what will cause an amendment?" Regfo answers with a structured list — citation, severity, which study report triggered it, and what to do about it. Weave Bio covers the same ground as part of its broader submissions module. The question is whether you need a focused gap analysis this week or an integrated submissions workspace for the next year.
Regfo
Paragraph-level citations, 46 data points extracted per study.
Weave Bio
Integrated with the rest of the submission lifecycle.
Pricing and buyer profile
Weave Bio publishes no pricing and sells enterprise contracts through a demo. We estimate ACVs in the six figures, which is typical for regulatory platforms at that stage — treat it as an estimate, not a quote. Regfo is priced for the emerging biotech that has raised a Series A or B and needs to file an IND with a team of one to ten. If your CFO is still counting seats on Notion, $999/mo reads very differently from an enterprise contract.
Regfo
Free ($0), Pro ($399/mo), Team ($999/mo). 20% off annual. No setup fees, no implementation contracts.
Weave Bio
Enterprise-oriented — suited to bigger budgets and teams.